Related Experiment Video

Updated: Jul 17, 2026

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Mutational analysis of PTPRT phosphatase domains in common human cancers

Jong Woo Lee1, Eun Goo Jeong, Sung Hak Lee

  • 1Department of Pathology, College of Medicine, Catholic University of Korea, Seoul, Korea.

APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica
|January 17, 2007
PubMed

Insights

Somatic mutations in the protein-tyrosine phosphatase, receptor-type, T (PTPRT) gene are rare in common human cancers. This suggests PTPRT mutations may not be a critical factor in the development of most cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The protein-tyrosine phosphatase, receptor-type, T (PTPRT) gene has been implicated as a potential tumor suppressor due to somatic mutations in some cancers.
  • Previous research on PTPRT mutations primarily focused on colon cancer, leaving data on other cancer types limited.

Purpose of the Study:

  • To investigate the frequency and types of PTPRT phosphatase domain mutations across a broader spectrum of common human cancers.
  • To evaluate the role of PTPRT mutations in the pathogenesis of various cancer types.

Main Methods:

  • A mutational analysis of the PTPRT phosphatase domain was conducted using polymerase chain reaction-based single-strand conformation polymorphism (PCR-SSCP) assay.
  • The study analyzed 345 cases of common human cancers, including colon, gastric, liver, leukemia, breast, and non-small cell lung cancers.

Main Results:

  • PTPRT phosphatase domain mutations were detected in 1 out of 105 colon carcinomas (1%) and 1 out of 48 gastric carcinomas (2%).
  • No PTPRT mutations were found in hepatocellular carcinomas, acute leukemias, breast carcinomas, or non-small cell lung cancers.
  • The identified mutations included a missense mutation in colon cancer and a splice-site mutation in gastric cancer.

Conclusions:

  • Somatic mutations in the PTPRT phosphatase domain are rare in the common human cancers examined.
  • Alterations in the PTPRT-mediated signaling pathway due to PTPRT phosphatase domain mutations likely do not play a critical role in the development of most common human cancers.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...